logo-loader
viewRedx Pharma Plc

Redx Pharma's Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott after announcing they've sold one of their cancer research programmes for up to US$203mln.

The agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) has a tiered payment structure and will see Redx receive a upfront sum of US$3.5mln.

Quick facts: Redx Pharma Plc

Price: 7.75 GBX

AIM:REDX
Market: AIM
Market Cap: £9.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

on 19/11/19

RNS

Result of General Meeting

12 hours, 54 minutes ago

Form 8.3 - Redx Pharma plc

5 days, 16 hours ago

Form 8.3 - Redx Pharma PLC

6 days, 9 hours ago

Form 8.3 - Redx Pharma Plc

6 days, 11 hours ago

Form 8.3 - Redx Pharma plc

6 days, 11 hours ago

Form 8.3 - Redx Pharma plc

1 week, 5 days ago

Form 8.5 (EPT/RI)

1 week, 6 days ago

2 min read